High Times
Home > Boards > US Listed > Biotechs >

Viking Therapeutics, Inc. (VKTX)

Add VKTX Price Alert      Hide Sticky   Hide Intro
Moderator: DMOST, greens12
Search This Board: 
Last Post: 10/19/2018 11:39:25 PM - Followers: 65 - Board type: Free - Posts Today: 0

Novel therapeutics for metabolic<Br/>and endocrine disorders
  1. 2


Viking Therapeutics is focused on the development of novel therapeutics for patients suffering from metabolic and endocrine disorders.

Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of patients recovering from non-elective hip fracture surgery. The Company’s second program is focused on the development of first-in-class, selective, small molecule agonists of the thyroid receptor beta, or TRß, for adrenoleukodystrophy, or ALD, and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis, or NASH. Viking is also developing additional programs targeted at diabetes, metabolic diseases and anemia.



We have a portfolio of five drug candidates in clinical trials or preclinical studies

Our lead clinical program, VK5211, is a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 is designed to produce the therapeutic benefits of testosterone in muscle and bone with improved safety, tolerability and patient acceptance. We have initiated a Phase 2 clinical trial with VK5211 in patients recovering from non-elective hip fracture surgery. For more information on this study please visit NCT02578095.

Our second pipeline program is focused on the development of novel small molecule agonists of the thyroid beta (TRb) receptor, VK2809 and VK0214. These novel TRb agonists are being developed for hypercholesterolemia and fatty liver disease and X-linked adrenoleukodystrophy, or X-ALD. We have initiated Phase 2 clinical development of VK 2809 in hypercholesterolemia and fatty liver disease. VK0214 is in preclinical development for X-ALD.

We are also developing VK0612, a first-in-class, orally available drug 

High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VKTX News: Statement of Ownership (sc 13g) 10/10/2018 10:06:38 AM
VKTX News: Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting ... 10/08/2018 07:02:00 AM
VKTX News: Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting®... 10/04/2018 07:02:00 AM
VKTX News: Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Pr... 10/01/2018 07:02:00 AM
VKTX News: Viking Therapeutics to Participate in Upcoming Investor Conferences 09/26/2018 07:35:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1549  Sticky Note Viking Therapeutics stock rose 87% on results for DMOST 09/18/18 08:58:57 PM
#1640   LOL Touche. That is true. My irritation ShawnTrade 10/19/18 11:39:25 PM
#1639   NASH Opportunity Driving Growth for Viking Therapeutics in 2018 DMOST 10/19/18 04:13:49 PM
#1638   Viking Therapeutics: A Valuation greens12 10/19/18 11:14:01 AM
#1637   Lol...well said. kris_kade 10/18/18 06:33:11 PM
#1636   You are right - from this time last MasterSalix 10/18/18 05:55:16 PM
#1635   Management are losers with this company. Every day ShawnTrade 10/18/18 02:26:23 PM
#1634   3 Top Small-Cap Stocks to Buy in October DMOST 10/14/18 11:25:32 PM
#1633   Here's Why Viking Therapeutics Skyrocketed 33% in September DMOST 10/12/18 03:01:55 PM
#1632   The Gap is getting filled now....a swing back greens12 10/11/18 02:14:05 AM
#1631   There will be a 3Q conference call early bigjake 10/10/18 05:12:47 PM
#1630   Are there any known news events between now IRAHopeful 10/10/18 01:09:16 PM
#1629   I wont be suprised to see a short greens12 10/09/18 11:08:48 AM
#1628   Down in $10 range. investor86 10/09/18 08:58:35 AM
#1627   Where is that gap? Cuppy 10/09/18 08:57:34 AM
#1626   I won't be surprised if gap fills. investor86 10/09/18 08:32:55 AM
#1625   News fade away, investors are taking profits. investor86 10/09/18 08:32:09 AM
#1624   Any insights as to what's going here? Sncgolf03 10/08/18 09:21:17 PM
#1623   Why? Despite the indicators and charts........ VKTX news and prospects DMOST 10/08/18 10:36:24 AM
#1622   If support $15 brakes this will get ugly. investor86 10/08/18 10:25:02 AM
#1621   Viking Therapeutics Announces Data from In Vivo Study DMOST 10/08/18 08:47:47 AM
#1620   Zacks research... http://scr.zacks.com/News/Press-Releases/Press-Release-Details greens12 10/03/18 06:42:07 PM
#1619   Who’s Following Viking Therapeutics’ NASH Pipeline? DMOST 10/03/18 03:53:05 PM
#1618   How Viking Therapeutics Is Positioned in 2018 DMOST 10/03/18 03:49:46 PM
#1617   VKTX: Presentation of Full Data Set for VK5211 DMOST 10/03/18 03:48:02 PM
#1616   Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and MasterSalix 10/02/18 01:20:56 PM
#1615   Info taken from Seeking Alpha and the NGMBio website. IRAHopeful 10/02/18 01:04:51 PM
#1614   I don't see where this release says anything bigjake 10/02/18 02:34:40 AM
#1613   My understanding was different. I believe VKTX last bigjake 10/02/18 02:28:50 AM
#1612   Viking Therapeutics Presents Results from Phase 2 Study greens12 10/02/18 12:00:45 AM
#1611   Have not heard about specific date but was greens12 10/01/18 11:56:41 PM
#1610   Has anyone seen whether or not they've had bigjake 10/01/18 05:22:59 PM
#1609   As usual, weak hand manipulation. On positive DMOST 10/01/18 01:22:48 PM
#1608   Why the drop today. I was anticipating Sncgolf03 10/01/18 01:01:56 PM
#1607   My $15 target is getting closer and closer. investor86 10/01/18 11:17:04 AM
#1606   The Greatest Healthcare Stocks of the 21st Century greens12 09/27/18 11:31:15 AM
#1605   http://www.asbmr.org/ItineraryBuilder/Sessions.aspx Viking presents Phase 2 hip billionairewannabe 09/27/18 10:40:14 AM
#1604   5 Biotech Stocks to Play the Sector’s Next DMOST 09/27/18 08:28:22 AM
#1603   Waffles , Any thoughts on this article that greens12 09/26/18 09:42:58 PM
#1602   Forget Tilray, These 2 Biotech Stocks Have Far DMOST 09/25/18 05:09:14 PM
#1601   Yes Sir.....But many feel between $75-$100 to be DMOST 09/25/18 01:53:32 PM
#1600   From 2 Billion to 4 billion in worldwide greens12 09/25/18 11:34:16 AM
#1599   Good quote DMOST and great Zachs research by billionairewannabe 09/24/18 09:27:25 PM
#1598   Based on the results of the Phase 2 DMOST 09/24/18 01:58:54 PM
#1597   Thanks , I do see R.J has a greens12 09/22/18 02:17:02 PM
#1596   Check on Finviz or Briefing. The upgrade came gman55423 09/22/18 01:47:56 PM
#1595   Can you get me a link to that greens12 09/22/18 01:17:32 PM
#1594   Yes. You are wrong. nsomniyak 09/22/18 12:39:51 PM
#1593   Raymond James did a reiterate outperform on Viking gman55423 09/22/18 09:32:22 AM
#1592   I agree with you 100%....The whales control this greens12 09/22/18 01:15:56 AM
#1591   Hey buddy, good to see you posting again, greens12 09/22/18 01:10:32 AM